270 related articles for article (PubMed ID: 17275980)
1. Applications of Botulinum toxin in urogynaecology.
Sinha D; Karri K; Arunkalaivanan AS
Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):4-11. PubMed ID: 17275980
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
3. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
da Silva CM; Cruz F
Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
6. [Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility].
Mazo EB; Krivoborodov GG; Efremov NS
Ter Arkh; 2008; 80(10):49-52. PubMed ID: 19105415
[TBL] [Abstract][Full Text] [Related]
7. Botulinum neurotoxin type A: the poison that can treat the sick.
Novara G
Eur Urol; 2009 Mar; 55(3):560-2. PubMed ID: 18805630
[No Abstract] [Full Text] [Related]
8. Botulinum toxin for the treatment of lower urinary tract symptoms: a review.
Sahai A; Khan M; Fowler CJ; Dasgupta P
Neurourol Urodyn; 2005; 24(1):2-12. PubMed ID: 15578628
[TBL] [Abstract][Full Text] [Related]
9. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin treatment of urethral and bladder dysfunction.
Chuang YC; Smith CP; Somogyi GT; Chancellor MB
J Formos Med Assoc; 2003 Jan; 102(1):5-11. PubMed ID: 12684605
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
Lee JC; Yokoyama T; Hwang HJ; Arimitsu H; Yamamoto Y; Kawasaki M; Takigawa T; Takeshi K; Nishikawa A; Kumon H; Oguma K
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):201-11. PubMed ID: 17692094
[TBL] [Abstract][Full Text] [Related]
12. The case for bladder botulinum toxin application.
Kim DK; Thomas CA; Smith C; Chancellor MB
Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
[TBL] [Abstract][Full Text] [Related]
13. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
14. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
[TBL] [Abstract][Full Text] [Related]
15. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance.
Tsai SJ; Ying TH; Huang YH; Cheng JW; Bih LI; Lew HL
Arch Phys Med Rehabil; 2009 May; 90(5):832-6. PubMed ID: 19406304
[TBL] [Abstract][Full Text] [Related]
16. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
[TBL] [Abstract][Full Text] [Related]
17. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
Cruz F; Dinis P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):920-7. PubMed ID: 17705161
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
[TBL] [Abstract][Full Text] [Related]
19. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
[TBL] [Abstract][Full Text] [Related]
20. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
